Zantac cancer concerns halt shipments of generic versions of popular heartburn medication
September 21 2019, 08:00
A division of Novartis, a pharmaceutical company based in Switzerland, has halted shipments of generic versions of the heartburn medication Zantac after the Food and Drug Administration (FDA) recently announced it found trace amounts of a potentially cancer-causing chemical in the product.
A division of Novartis, a pharmaceutical company based in Switzerland, has halted shipments of generic versions of the heartburn medication Zantac after the Food and Drug Administration (FDA) recently announced it found trace amounts of a potentially cancer-causing chemical in the product.
Source:
FOX News